Clearmind Medicine shares jump 22.70% intraday after completing treatment and follow-up for 18 participants in Phase I/IIa trial of CMND-100.

Clearmind Medicine surged 22.70% intraday following multiple announcements regarding the successful completion of treatment and follow-up for 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100 for alcohol use disorder. The updates indicate progress in the company’s core therapeutic development, signaling to investors a positive development in its clinical pipeline. These developments are seen as a key milestone for early-stage research and may enhance the therapeutic potential of CMND-100, contributing to the sharp intraday rally.